Fate Therapeutics

In News

Fate’s off-the-shelf CAR-T therapy shows early promise in treatment-resistant autoimmune disease - Fierce Biotech

Fierce Biotech - Jul 09, 2026

Fate Therapeutics Stock Pops As FT836 Cancer Data Impress Traders - StocksToTrade

StocksToTrade - Jun 28, 2026

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences - Yahoo Finance

Yahoo Finance - Jul 01, 2026

Fate Therapeutics Gets FDA Clearance for FT839 Autoimmune CAR-T Therapy - The Clinical Trial Vanguard

The Clinical Trial Vanguard - Jul 10, 2026

BlackRock, Inc. Reduces Stake in Fate Therapeutics Inc - GuruFocus

GuruFocus - Jul 15, 2026

Fate Therapeutics Wins FDA IND Clearance for FT839, a Dual-CAR T-Cell Therapy for Autoimmune Disease - BioPharm International

BioPharm International - Jul 09, 2026

FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials - Stocktwits

Stocktwits - Jul 14, 2026

Fate Therapeutics Selected for U.S. FDA Chemistry, - GlobeNewswire

GlobeNewswire - May 05, 2026

FT819 Remodels Lupus B Cells in Clinical Trial - CRISPR Medicine News

CRISPR Medicine News - May 13, 2026

H.C. Wainwright reiterates Fate Therapeutics stock rating at buy - Investing.com

Investing.com - Jul 10, 2026

H.C. Reiterates “Buy” Rating On Fate Therapeutics (FATE) With $7 PT - Yahoo Finance

Yahoo Finance - Jun 10, 2026

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate - GlobeNewswire

GlobeNewswire - Jul 09, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment